V. Upreti

发表

Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective

J. Gokemeijer, H. Mody, V. Jawa, 2023, Clinical pharmacology and therapeutics.

New styryl sulfones as anticancer agents.

A. K. Reka, Gopalakrishnan Bulusu, Akash Khandelwal, 2003, European journal of medicinal chemistry.

Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors

S. Dutta, V. V. Upreti, J. Kast, 2021, Advances in Therapy.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF‐1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study

M. L. Srinivas, R. Digumarti, N. Srinivas, 2004, Journal of clinical pharmacology.

The Potential Role of the J‐Tpeak Interval in Proarrhythmic Cardiac Safety: Current State of the Science From the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium

P. Sager, D. Strauss, J. Vicente, 2019, Journal of clinical pharmacology.

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

C. Frost, Jessie Wang, F. LaCreta, 2013, Clinical pharmacology : advances and applications.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

C. Frost, Jessie Wang, Y. Barrett, 2013, British journal of clinical pharmacology.

Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.

N. Srinivas, V. V. Upreti, R. Mamidi, 2003, Biomedical chromatography : BMC.

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma

S. Dutta, M. Ahamadi, V. V. Upreti, 2022, CPT: pharmacometrics & systems pharmacology.

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

R. Sullivan, K. Flaherty, Douglas B. Johnson, 2022, Investigational New Drugs.

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer

S. Dutta, H. Prenen, V. V. Upreti, 2021, Cancer Chemotherapy and Pharmacology.

Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not

S. Dutta, H. Prenen, V. V. Upreti, 2020, Clinical pharmacology : advances and applications.

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Andy Z. X. Zhu, Yuan Chen, E. Schuck, 2019, CPT: pharmacometrics & systems pharmacology.

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development

S. Dutta, M. Ahamadi, V. V. Upreti, 2022, Clinical and translational science.

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

Alison Johnson, K. Stubenrauch, C. Xia, 2022, Molecular therapy. Methods & clinical development.

An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies Development

J. Gokemeijer, V. Jawa, Swati Gupta, 2023, Clinical pharmacology and therapeutics.

Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling

V. V. Upreti, Jan Wahlstrom, V. Upreti, 2016, Journal of clinical pharmacology.

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

N Parrott, H M Jones, Y Chen, 2015, Clinical pharmacology and therapeutics.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

E. Rasmussen, P. LoRusso, B. Tran, 2018, Journal of Immunotherapy for Cancer.

Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage.

B. Song, N. Eddington, V. V. Upreti, 2010, Current pharmaceutical biotechnology.

Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects

F. LaCreta, D. Boulton, Ming Chang, 2013, Clinical Drug Investigation.

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII

T. Cloughesy, E. Rasmussen, D. Reardon, 2019, Cancer Chemotherapy and Pharmacology.

VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats.

P. Purushottamachar, A. Khandelwal, L. Gediya, 2014, European journal of pharmacology.

Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

L. Byers, N. Sadraei, Di Zhou, 2023, Journal of clinical pharmacology.

Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

T. Prisinzano, H. Hassan, N. Eddington, 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.